News
AVXL
2.760
+6.98%
0.180
Anavex Life Sciences: Waiting On Validation As Blarcamesine Shows Some Promise
Seeking Alpha · 5d ago
Weekly Report: what happened at AVXL last week (0622-0626)?
Weekly Report · 5d ago
Anavex Sets 2026 Annual Meeting and Record Date
TipRanks · 06/26 10:49
Anavex Life Sciences sets 2026 annual shareholder meeting
PUBT · 06/26 10:19
Weekly Report: what happened at AVXL last week (0615-0619)?
Weekly Report · 06/22 10:10
U.S. Earnings Preview: Before Market Open June 16
Dow Jones · 06/16 09:31
Weekly Report: what happened at AVXL last week (0608-0612)?
Weekly Report · 06/15 10:11
Weekly Report: what happened at AVXL last week (0601-0605)?
Weekly Report · 06/08 10:07
U.S. Earnings Preview: Before Market Open June 2
Dow Jones · 06/02 09:31
Weekly Report: what happened at AVXL last week (0525-0529)?
Weekly Report · 06/01 10:11
U.S. Earnings Preview: Before Market Open May 26
Dow Jones · 05/26 09:31
Weekly Report: what happened at AVXL last week (0518-0522)?
Weekly Report · 05/25 10:14
Anavex Faces Nasdaq Compliance Pressure Over Late Filing
TipRanks · 05/22 12:47
Anavex Life Sciences receives Nasdaq delinquency notice
Seeking Alpha · 05/22 12:30
Anavex receives Nasdaq delinquency notice over late quarterly filing
PUBT · 05/22 12:16
Anavex receives expected Nasdaq delinquency notification
TipRanks · 05/22 12:13
Anavex delays filing quarterly Form 10-Q after missing deadline
PUBT · 05/22 12:01
ANAVEX LIFE SCIENCES RECEIVES EXPECTED NASDAQ DELINQUENCY NOTIFICATION
Reuters · 05/22 12:00
U.S. Earnings Preview: Before Market Open May 19
Dow Jones · 05/19 09:31
Anavex options imply 6.3% move in share price post-earnings
TipRanks · 05/18 18:07
More
Webull provides a variety of real-time AVXL stock news. You can receive the latest news about Anavex Life Scie through multiple platforms. This information may help you make smarter investment decisions.
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.